Masayuki Noritake

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat, Youssef M.K. Farag et autres

BACKGROUND: In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular and kidney failure outcomes. Finerenone also lowers the urine albumin-to-creatinine ratio (UACR). Whether finerenone-induced change in UACR mediates cardiovascular and kidney …

us, gb, de, es, dk, gr, pl (code pays fourni par la source)

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D. Anker et autres

In Fig. 2 of the article cited above, due to a typographical error, the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59–0.94) instead of the correct …

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt et autres

OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) …

dk, de, gr, us, es, gb (code pays fourni par la source)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos et autres

OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA1c level and insulin treatment …

dk, ca, us, de, gr, es, be, au, il (code pays fourni par la source)

Insulin‐derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases

Terumasa Nagase, Keiichi Iwaya, Koichiro Kogure, Tamotsu Zako et autres

To date, almost all case reports of insulin-derived amyloidosis described the presence of a subcutaneous mass that was observable on physical examination. This report presents two cases of insulin-derived amyloidosis without palpable masses at insulin injection sites. In both cases, blood glucose …

jp (code pays fourni par la source)

Toxicity of insulin-derived amyloidosis: a case report

Keiichi Iwaya, Tamotsu Zako, Junta Fukunaga, Karin Sörgjerd et autres

BACKGROUND: Insulin-derived amyloidosis is a skin-related complication of insulin therapy that interferes with insulin therapy. Although toxicities of in vitro-formed insulin amyloid fibrils have been well studied, the toxicity of insulin-derived amyloidosis remains to be clarified. CASE PRESENTATION: A 58-year-old man with …

jp (code pays fourni par la source)

Clinical and MRI characteristics and follow-up studies of insulin-derived amyloidosis

Terumasa Nagase, Keiichi Iwaya, Tamotsu Zako, Tomotada Odaka et autres

"Clinical and MRI characteristics and follow-up studies of insulin-derived amyloidosis." Amyloid, 26(sup1), pp. 156–157

jp (code pays fourni par la source)

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher et autres

OBJECTIVE This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin in patients with inadequately controlled type 1 diabetes (HbA1c 7.5–10.5%). RESEARCH DESIGN AND METHODS Patients were randomized 1:1:1 to …

be, us, ca, de, jp, se, gb (code pays fourni par la source)

Insulin-derived Amyloidosis and Poor Glycemic Control: A Case Series

Terumasa Nagase, Keiichi Iwaya, Yoshiki Iwaki, Fumio Kotake et autres

OBJECTIVES: Insulin-derived amyloidosis is a rare skin-related complication of insulin therapy. The purpose of this study was to show the effects of insulin-derived amyloidosis on blood glucose levels, insulin dose requirements, and insulin absorption. METHODS: Seven patients were found to have insulin-derived …

jp (code pays fourni par la source)

Effects of Combined Therapies with Protein-Bound Polysaccharide (PSK, Krestin®) and Fluorinated Pyrimidine Derivatives on Experimental Liver Metastases and on the Immunologic Capacities of the Hosts

S Tsuru, Nariyoshi Shinomiya, Yoshiya Katsura, Masayuki Gotoh et autres

An experimental model is introduced for the study of liver metastases using intrasplenically injected EL-4 and Lewis lung tumor cells. Fluorinated pyrimidine derivatives, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil, showed inhibitory effects on the frequencies of liver metastases. Immunosuppressive effects of these drugs were compared …

cz, jp (code pays fourni par la source)

Author Index

P. Lissoni, Sandro Barni, Maria Grazia Cattaneo, G. Tancini et autres

The insulin ball

Terumasa Nagase, Yoshiya Katsura, Yoshiki Iwaki, Kenji Nemoto et autres

jp (code pays fourni par la source)